Aptorum Group Limited (APM)

NASDAQ: APM · IEX Real-Time Price · USD
8.96
+0.26 (2.93%)
Mar 28, 2024, 10:35 AM EDT - Market open
2.93%
Market Cap 45.86M
Revenue (ttm) 1.20M
Net Income (ttm) -13.40M
Shares Out 4.17M
EPS (ttm) -3.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 67,556
Open 8.70
Previous Close 8.70
Day's Range 8.51 - 9.30
52-Week Range 1.35 - 17.49
Beta -0.01
Analysts n/a
Price Target n/a
Earnings Date Apr 26, 2024

About APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The c... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 18, 2018
Employees 18
Stock Exchange NASDAQ
Ticker Symbol APM
Full Company Profile

Financial Performance

In 2022, Aptorum Group's revenue was $1.30 million, a decrease of -15.95% compared to the previous year's $1.54 million. Losses were -$9.80 million, -60.88% less than in 2021.

Financial Statements

News

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced t...

22 days ago - Business Wire

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncol...

3 months ago - Business Wire

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...

3 months ago - Business Wire

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...

4 months ago - Business Wire

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Na...

8 months ago - Business Wire

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the t...

10 months ago - Business Wire

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (the “Company”) (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading...

10 months ago - Business Wire

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...

11 months ago - Business Wire

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary A...

11 months ago - Business Wire

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to...

11 months ago - Business Wire

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that it entered into a non-binding...

1 year ago - Business Wire

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) and ASP Isotopes Inc. (Nasdaq:ASPI) on The RedChip Mon...

Other symbols: ASPI
1 year ago - Accesswire

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...

1 year ago - Business Wire

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...

1 year ago - Business Wire

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the devel...

1 year ago - Business Wire

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...

1 year ago - Business Wire

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Announces 1-for-10 Reverse Stock Split

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(Euronext Paris:APM), a clinical stage biopharmaceutical company dedicated t...

1 year ago - Accesswire

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

1 year ago - Business Wire